1. Home
  2. LPSN vs NCEL Comparison

LPSN vs NCEL Comparison

Compare LPSN & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$1.86

Market Cap

21.6M

Sector

Technology

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$3.48

Market Cap

22.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPSN
NCEL
Founded
1995
2008
Country
United States
Switzerland
Employees
N/A
4
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
22.0M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
LPSN
NCEL
Price
$1.86
$3.48
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
64.2K
33.1K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$249,838,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$1.83
52 Week High
$7.54
$5.12

Technical Indicators

Market Signals
Indicator
LPSN
NCEL
Relative Strength Index (RSI) 51.63 41.65
Support Level $1.80 $2.58
Resistance Level $2.44 $3.70
Average True Range (ATR) 0.09 0.34
MACD 0.02 -0.07
Stochastic Oscillator 90.22 7.32

Price Performance

Historical Comparison
LPSN
NCEL

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: